Τhe impact of variations of KRAS G12/G13 mutation load in cfDNA in the monitoring of tumor burden was investigated in a subset of 14 NSCLC patients with detectable plasma KRAS G12/G13 mutations at baseline (T0). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.